A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Recruiting

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

Trial locations(7 sites)

United States

University of Kansas, Westwood, Kansas

Washington University, St Louis, Missouri

SCRI, San Antonio, Texas

University of Utah, Salt Lake City, Utah

Australia

Royal Prince Alfred, Camperdown, New South Wales